Rollins Financial Eli Lilly & CO Transaction History

Rollins Financial

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	SELL	$525.19 - $619.13 $231,608 - $273,036	-441 Reduced 36.06%	782 $455,000
Q3 2023 Nov 09, 2023	BUY	$434.7 - $599.3 $254,734 - $351,189	586 Added 91.99%	1,223 $656,000
Q2 2023 Aug 08, 2023	BUY	$350.74 - $468.98 $223,421 - $298,740	637 New	637 $298,000
Q4 2022 Feb 06, 2023	BUY	$321.55 - $374.67 $187,785 - $218,807	584 New	584 $213,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Rollins Financial, based on Form 13F filings with the SEC.

Stay updated on Rollins Financial with notifications on news.